Abstract
Zollinger-Ellison syndrome (ZES) is caused by a tumor that secretes gastrin and is the most common of the malignant islet cell tumors. ZES leads to hypergastrinemia, which, in turn, causes an overproduction of gastric acid and results in complications of peptic ulcer disease. Of all the islet cell tumors, gastrinoma tumors have undergone the most extensive study, providing a model of tumor management. Increased awareness and improved biochemical and radiologic techniques mean that these disorders are being recognized in more patients. Advances in the management of gastric acid secretion and new localization methods have significantly reduced the morbidity and mortality associated with ZES. The use of intravenous proton pump inhibitors such as pantoprazole will make surgical and perioperative management more favorable for patients. Radiologic and nuclear medicine studies permit the detection of the majority of islet cell tumors and improve the ability for surgical resection. With the recent cloning of the gene for multiple endocrine neoplasia type I (MEN- I) and the recognition of tumor markers associated with the development of islet cell tumors, early detection of these tumors may someday be possible.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
O'Conner DT, Deftos LJ: Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 1986, 314:1145–1151.
Del Valle, J, Yamada T: Zollinger-Ellison Syndrome. In Textbook of Gastroenterology. Edited by Yamada T. Philadelphia: JB Lippincott; 1991:1912–1928.
Lam KY, Lo CY: C-erb-2 protein expression in oesophageal squamous epithelium from esophageal squamous cell carcinomas, with special reference to histological grade of carcinoma and pre-invasive lesion Eur J Surg Oncol 1997, 23 36–42.
Boden G: Insulinoma and glucagonoma. Semin Oncol 1987, 14:253–262.
Hirschowitz BI: Zollinger-Ellison syndrome: pathogenesis diagnosis, and management. Am J Gastroenterol 1997, 92(suppl):44S-48S.
Pisegna JR, de Weerth A, Huppi K, et al.: Molecular cloning of the human brain and gastric cholecystokinin receptor: structure, functional expression and chromosomal localization. Biochem Biophys Res Comm 1992, 189:296–303.
Wank SA, Pisegna JR, de Weerth A: Molecular cloning of the rat cholecystokinin type B receptor: structure, and functional expression. Proc Natl Acad Sci 1992, 89: 8691–8695.
Zeng N, Kang T, Wong H, et al.: The pituitary adenylate cyclase activating polypeptide type 1 receptor (PAC1) is expressed on gastric ECL cells: evidence by immunocytochemistry and RT-PCR. Ann N Y Acad Sci 1998, 865:147–156. This study demonstrates that the novel neuropeptide, PACAP, has a significant role in the regulation of gastric acid secretion.
Bloom SR, Long RG, Bryant MG, et al.: Clinical, biochemical and pathological studies on 62 VIPomas. Gastroenterology 1980, 78:1143.
Fishbeyn VA, Norton JA, Benya RV, et al.: Assessment and prediction of long-term cure in patients with the Zollinger- Ellison syndrome: the best approach. Ann Intern Med 1993, 119:199–206.
Fass R, Rosen HR, Walsh JH: Zollinger-Ellison syndrome: diagnosis and management. Hosp Pract 1995, 30:73–80.
Pisegna JR, Norton JA, Slimak GG, et al.: Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology 1992, 102:767–778.
Metz DC, Pisegna JR, Fishbeyn VA, et al.: Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 1992, 103:1498–1508.
Frucht H: Use of omeprazole in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1991, 36:394.
Stewart CA, Termanini B, Sutliff VE, et al.: Management of the Zollinger-Ellison syndrome in pregnancy. Am J Obstet Gynecol 1997, 176:224–233. This study is the first to demonstrate the safety of ranitidine during pregnancy.
Maton, PN: Zollinger-Ellison syndrome: recognition and management of acid hypersecretion. Drugs 1996, 52:33–44.
Metz DC, Lew E, Forsmark CE, et al.: Intravenous (IV) pantoprazole (PANTO) rapidly and effectively controls acid output (AO) in patients with Zollinger-Ellison syndrome (ZES). Gastroenterology 1998, 114:G0926. This study is important for its examination of the acute management of gastric acid hypersecretion in patients with ZES. The authors demonstrate that the new proton pump inhibitor, pantoprazole, can be safely used to treat patients with ZES.
Pisegna JR, Huang, M, Asvar C, et al.: Inhibition of pentagastrin-induced gastric acid hypersecretion by single-dose intravenous pantoprazole compared with single-dose intravenous famotidine and placebo in healthy subjects. Gastroenterology 1998, 114:G1065.
Pisegna JR, Doppman JL, Norton JA, et al.: Prospective comparative study of ability of MR imaging and other imaging modalities to localize tumors in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1993, 38:1318–1328.
Townsend CM, Thompson JC: Surgical management of tumors that produce gastrointestinal hormones. Ann Rev Med 1985, 36:111–124.
Norton JA, Fraher DL, Alexander R, et al.: Surgery to cure: th Zollinger-Ellison syndrome. N Engl J Med 1999, 341:635–644. This report describes one of the most complete clinical studies examining the role of surgery to cure ZES. The authors have significant experience in the surgical management of this syndrome and offer a review of the most up-to-date methods for surgical cure of these patients.
Thompson NW: Surgical treatment of the endocrine pancreas and Zollinger-Ellison syndrome in the MEN 1 syndrome. Henry Ford Hosp Med J 1992, 40:195–198.
Frucht H, Norton JA, London JF, et al.:Detection of duodenal gastrinomas by operative endoscopic transillumination: a prospective study. Gastroenterology 1990, 99:1622–1627.
Straus E, Raufman JP, Samuel S, et al.: Endoscopic cure of the Zollinger-Ellison syndrome. Gastrointest Endosc 1992, 38:709–711.
Benya RV, Metz DC, Hijazi YM, et al.: Fine needle aspiration cytology of submucosal nodules in patients with Zollinger- Ellison syndrome. Am J Gastroenterol 1993, 88:258–265.
Barton JC, Hirschowitz BI, Maton PN, et al.: Bone metastases in malignant gastrinoma. Gastroenterology 1986, 91:1179–1185.
Reubi JC, Kvols LK, Nagorney DM, et al.: Detection of somatostatin receptor in surgical and percutaneous needle biopsy of samples of carcinoid and islet cell carcinomas. Cancer Res 1990, 50:5969–5977.
Redding TW, Schally AV: Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc Natl Acad Sci U S A 1984, 84:248–252.
Saltz L, Trochanowski B, Buckley M, et al.: Octerotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 1993, 72:244–248.
Arnold R, Trautmann ME, Creutzfeldt W, et al.: Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996, 38:430–438.
Anderson JV, Bloom SR: Treatment of malignant endocrine tumors with human leukocyte interferon. Lancet 1987, 1:97.
Eriksson B, Alm G, Lundqvist G, et al.: Treatment of malignant endocrine pancreatic tumors with human leukocyte interferon. Lancet 1986, 2:1307–1309.
Pisegna JR, Slimak GG, Doppman JL, et al.: An evaluation of human recombinant alpha interferon in patients with metastatic gastrinoma. Gastroenterology 1993, 105:1179–1183.
Creutfeldt W, Bartsch HH, Jacubaschke U, et al.: Treatment of gastrointestinal endocrine tumors with interferon-alpha and octreotide. Acta Oncol 1991, 30:529–535.
Nold R, Frank M, Kajdan U, et al.: Combined treatment of metastatic endocrine tumors of the gastrointestinal tract with octreotide and interferon-alpha. Gastroenterology 1994, 32:193–197.
Frank M, Klose KJ, Wied M, et al.: Combination therapy with octreotide and a-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999, 94:1381–1387.
Moertel CG: Streptozocin-doxorubicin, streptozocinfluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992, 326:519–523.
von Schrenck T, Howard JM, Doppman JL, et al.: Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterology 1988, 94:1326–1334.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pisegna, J.R. The effect of Zollinger-Ellison syndrome and neuropeptide-secreting tumors on the stomach. Curr Gastroenterol Rep 1, 511–517 (1999). https://doi.org/10.1007/s11894-999-0012-8
Issue Date:
DOI: https://doi.org/10.1007/s11894-999-0012-8